



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

JFW

**POWER OF ATTORNEY  
and  
CORRESPONDENCE ADDRESS  
INDICATION FORM**

Application Number	10/770,727
Filing Date	February 2, 2004
First Named Inventor	Rong-Kun CHANG
Title	DRUG FORMULATION AND DELIVERY...
Art Unit	1623
Examiner Name	LEWIS, Patrick T.
Attorney Docket Number	029363.0002 formerly 41740-0802US

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

Practitioners associated with the Customer Number:

004372

OR

Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

The address associated with the above-mentioned Customer Number:

OR

The address associated with Customer Number:

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	Zip	
Country			
Telephone	Email		

I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)


**SIGNATURE of Applicant or Assignee of Record**

Signature		Date	12 June 2007
Name	Padmanabh P. Bhatt, Ph.D.	Telephone	301-838-2630
Title and Company	Supernus Pharmaceuticals Inc.		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

\*Total of \_\_\_\_\_ forms are submitted.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant/Patent Owner: Rong-Kun CHANG

Application No./Patent No.: 10/770,727

Filed/Issue Date: February 2, 2004

Entitled: Drug Formulation and Delivery Using Crystalline Methylated Cyclodextrins

Supernus Pharmaceuticals, Inc.

a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1.  the assignee of the entire right, title, and interest; or
2.  an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

A.  An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

B.  A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Shire Laboratories Inc. To: Supernus Pharmaceuticals, Inc.

The document was recorded in the United States Patent and Trademark Office at Reel 017596, Frame 0304, or for which a copy thereof is attached.

2. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

3. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

July 16, 2007  
Date

Patricia D. Granados  
Signature

Patricia D. Granados, Reg. No. 33,683

Typed or printed name

Registered Patent Attorney

Title



## United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)

## Assignments on the Web &gt; Patent Query

**Patent Assignment Abstract of Title**

**NOTE: Results display only for issued patents and published applications.**  
**For pending or abandoned applications please consult USPTO staff.**

**Total Assignments: 1**

Patent #: NONE

Issue Dt:

Application #: 10770727

Filing Dt: 02/02/2004

Publication #: 20040157797

Pub Dt: 08/12/2004

Inventor: Rong-Kun Chang

Title: DRUG FORMULATION AND DELIVERY USING CRYSTALLINE METHYLATED CYCLODEXTRINS

**Assignment: 1**

Reel/Frame: 017596/0304

Recorded: 05/10/2006

Pages: 46

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: SHIRE LABORATORIES, INC

Exec Dt: 04/25/2006

Assignee: SUPERNUS PHARMACEUTICALS, INC

1550 EAST GUDE DR

ROCKVILLE, MARYLAND 20850

Correspondent: ANNA GANELINA, SUPERNUS PHARMACEUTICALS

1550 EAST GUDE DR

ROCKVILLE, MD 20850

Search Results as of: 07/13/2007 02:14 PM

If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.0.1

Web interface last modified: April 20, 2007 v.2.0.1

[HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)